What is the Return on Assets (ROA) of Mesoblast this year?
The Return on Assets (ROA) of Mesoblast is -0.13 undefined this year.
Mesoblast ROA 2025
Mesoblast ROA
-0.13
Ticker
MSB.AX
ISIN
AU000000MSB8
WKN
A0DNPW
In 2025, Mesoblast's return on assets (ROA) was -0.13, a 7.45% increase from the -0.12 ROA in the previous year.
Mesoblast Aktienanalyse
What does Mesoblast do?
Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Mesoblast's Return on Assets (ROA)
Mesoblast's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Mesoblast's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Mesoblast's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Mesoblast’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Mesoblast stock
What was the ROA of Mesoblast compared to the previous year?
The ROA of Mesoblast has increased by 7.45% compared to the previous year.
What consequences do high ROA have for investors of Mesoblast?
A high ROA is advantageous for investors of Mesoblast, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Mesoblast?
A low ROA can be unfavorable for investors of Mesoblast as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Mesoblast affect the company?
An increase in ROA of Mesoblast can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Mesoblast impact the company?
A reduction in the ROA of Mesoblast can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Mesoblast?
Some factors that can influence the ROA of Mesoblast include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Mesoblast important for investors?
The ROA of Mesoblast is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Mesoblast take to improve ROA?
To improve ROA, Mesoblast can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Mesoblast pay?
Over the past 12 months, Mesoblast paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mesoblast is expected to pay a dividend of 0 USD.
What is the dividend yield of Mesoblast?
The current dividend yield of Mesoblast is .
When does Mesoblast pay dividends?
Mesoblast pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mesoblast?
Mesoblast paid dividends every year for the past 0 years.
What is the dividend of Mesoblast?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mesoblast located?
Mesoblast is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mesoblast kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mesoblast from 4/10/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/10/2025.
When did Mesoblast pay the last dividend?
The last dividend was paid out on 4/10/2025.
What was the dividend of Mesoblast in the year 2024?
In the year 2024, Mesoblast distributed 0 USD as dividends.
In which currency does Mesoblast pay out the dividend?
The dividends of Mesoblast are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mesoblast
Our stock analysis for Mesoblast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
